Levine Zurit 4
4 · COMPUGEN LTD · Filed Apr 13, 2026
Research Summary
AI-generated summary of this filing
Compugen (CGEN) SVP Levine Zurit Exercises Options, Sells Shares
What Happened
Levine Zurit, Senior Vice President, Business Development at Compugen Ltd. (CGEN), exercised options to acquire a total of 3,125 shares and sold 3,125 shares in the open market on April 10, 2026. The exercises were: 1,125 shares at $0.83 ($933) and 2,000 shares at $1.15 ($2,300), for a total cash cost of $3,233. The subsequent sale of 3,125 shares was executed at a weighted average price of $2.56, yielding $8,013. The filing also shows the derivative positions (the options) marked as disposed at $0, reflecting conversion/exercise of those options.
Key Details
- Transaction dates: April 10, 2026 (reported on Form 4 filed April 13, 2026).
- Exercises (M): 1,125 shares @ $0.83 = $933; 2,000 shares @ $1.15 = $2,300 (total acquired 3,125 shares for $3,233).
- Sale (S): 3,125 shares sold @ weighted avg $2.56 = $8,013 (prices ranged $2.50–$2.60; reporting person can provide per-share breakdown) (Footnote F2).
- Derivative disposition entries at $0 reflect conversion/exercise of the options (reported as disposed).
- Sale executed pursuant to a Rule 10b5-1 trading plan adopted Dec 23, 2025 (Footnote F1).
- Vesting notes: the two option grants have staged vesting schedules (Footnotes F3, F4).
- Shares owned after transaction: not stated in the provided excerpt of the filing.
Context
- This is an option exercise followed by an immediate open-market sale of the exercised shares (a common cashless exercise/monetization pattern).
- The sale was executed under a prearranged 10b5-1 plan, which typically pre-specifies timing/amounts and is often used to avoid questions about trading on material nonpublic information.
- Filing shows factual transaction details only; no inference about the Reporting Person’s view of the company should be assumed.
Insider Transaction Report
- Exercise/Conversion
Ordinary Shares
[F1]2026-04-10$0.83/sh+1,125$933→ 30,500 total - Exercise/Conversion
Ordinary Shares
[F1]2026-04-10$1.15/sh+2,000$2,300→ 32,500 total - Sale
Ordinary Shares
[F1][F2]2026-04-10$2.56/sh−3,125$8,013→ 29,375 total - Exercise/Conversion
Share Option (right to buy)
[F1][F3]2026-04-10−1,125→ 5,625 totalExercise: $0.83Exp: 2032-11-09→ Ordinary Shares (1,125 underlying) - Exercise/Conversion
Share Option (right to buy)
[F1][F4]2026-04-10−2,000→ 56,000 totalExercise: $1.15Exp: 2033-08-03→ Ordinary Shares (2,000 underlying)
Footnotes (4)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
- [F4]This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.